2024 Ophthalmic Revenue Roundup for Amgen and Biogen

Amgen Records 2024 Tepezza Revenue of $1.85 Billion

Amgen, of Thousand Oaks, California, reported Feb. 4 that its 2024 revenue for Tepezza was $1.85 billion.

2024 was the first full year of Tepezza sales for Amgen after the company closed its acquisition of Horizon Therapeutics on Oct. 6, 2023.

Amgen reported 2023 revenue for Tepezza of $448 million for the slightly shortened fourth quarter after its purchase.

Amgen’s Q4-2024 Tepezza revenue was $460 million.

Tepezza is the only approved treatment for thyroid eye disease in the US and Japan. It gained approval in Japan in September 2024.

The US made up $1.84 billion of 2025 revenue and $456 million of Q4-2024 revenue.

Amgen did not break out revenue for its Eylea biosimilar, Pavblu, launched in late 2024 over the objection of Eylea maker Regeneron. Pavblu is the only Eylea biosimilar available in the US market.

Amgen reported total 2024 revenue of $33.4 billion, a 19 percent increase over $28.2 billion in 2023.

Biogen Generates 2024 Revenue for Byooviz of $36.6 Million

Biogen, of Cambridge, Massachusetts, reported Feb. 12 that its 2024 revenue from Byooviz, a biosimilar to Lucentis, totaled $36.6 million, a 15.5 percent increase over $31.7 million in 2023, driven by increased adoption outside the US.

The US accounted for $23.0 million, a decrease from $29.2 million in 2023, while the rest of the world for accounted for $13.6 million, up from $2.5 million in 2023, when Byooviz became available in some international markets.

Q4-2024 revenue for Byooviz was $9.3 million, a 1.1 percent increase over $9.2 million in Q4-2023. The US accounted for $4.9 million, compared with $7.9 million in Q4-2023, while the rest of the world generated $4.4 million, compared with $1.3 million in Q4-2023.

Byooviz, the first approved ophthalmic biosimilar, became commercially available in the US in Q3-2022.